These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 2674982

  • 1. Combination therapy with flutamide and castration: its benefits at various stages of prostate cancer.
    Labrie F, Dupont A, Cusan L, Manhès G, Bergeron N, Lacourcière Y, Pineault S, Bélanger A, Monfette G, Emond J.
    Prog Clin Biol Res; 1989; 303():161-7. PubMed ID: 2674982
    [No Abstract] [Full Text] [Related]

  • 2. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F, Dupont A, Giguère M, Borsanyi JP, Lacourciere Y, Bélanger A, Lachance R, Emond J, Monfette G.
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [Abstract] [Full Text] [Related]

  • 3. Re Benefits of combination therapy with flutamide in patients relapsing after castration.
    Br J Urol; 1988 Nov; 62(5):495-6. PubMed ID: 3208035
    [No Abstract] [Full Text] [Related]

  • 4. Zoladex and flutamide vs orchidectomy: a phase III EORTC 30853 trial. EORTC Urological Group.
    Carvalho AP, de Moura JL, Denis L, Newling D, Smith P, Bono A, Sylvester R, De Pauw M, Ongena P.
    Prog Clin Biol Res; 1989 Nov; 303():129-43. PubMed ID: 2528736
    [No Abstract] [Full Text] [Related]

  • 5. Complete androgen blockade: data from an EORTC 30853 trial.
    Denis L, Keuppens F, Robinson M, Mahler C, Smith P, Pinto de Carvalho AP, Newling D, Bono A, Sylvester R, De Pauw M.
    Semin Urol; 1990 Aug; 8(3):166-74. PubMed ID: 2144656
    [No Abstract] [Full Text] [Related]

  • 6. [Complete androgen blockade (orchiectomy + flutamide) versus androgen blockade with cytostasis (orchiectomy + estramustine) in the treatment of virginal advanced prostate cancer].
    Flamm J, Fischer M.
    Wien Klin Wochenschr; 1988 Sep 09; 100(17):589-92. PubMed ID: 3055689
    [Abstract] [Full Text] [Related]

  • 7. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
    Labrie F, Dupont A, Giguere M, Borsanyi JP, Lacourciere Y, Belanger A, Lachance R, Emond J, Monfette G.
    J Steroid Biochem; 1987 Sep 09; 27(1-3):525-32. PubMed ID: 2961937
    [Abstract] [Full Text] [Related]

  • 8. Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer?
    Pavone-Macaluso M, Serretta V, Daricello G, Pavone C, Cacciatore M, Romano C, Cavallo N.
    Prog Clin Biol Res; 1990 Sep 09; 350():149-57. PubMed ID: 2201041
    [Abstract] [Full Text] [Related]

  • 9. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
    Blackledge G, Kolvenbag G, Nash A.
    Anticancer Drugs; 1996 Jan 09; 7(1):27-34. PubMed ID: 8742095
    [Abstract] [Full Text] [Related]

  • 10. 'Zoladex' versus 'Zoladex' plus flutamide in the treatment of advanced prostate cancer. First interim analysis of an international trial. International Prostate Cancer Study Group.
    Lunglmayr G.
    Prog Clin Biol Res; 1989 Jan 09; 303():145-51. PubMed ID: 2528737
    [Abstract] [Full Text] [Related]

  • 11. Combined androgen blockade: an update.
    Klotz L.
    Urol Clin North Am; 2006 May 09; 33(2):161-6, v-vi. PubMed ID: 16631454
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of surgical and biochemical castration and an antiandrogen on patients with stage D2 prostatic cancer: preliminary results.
    Givner ML, Millard OH.
    Prog Clin Biol Res; 1987 May 09; 243A():439-43. PubMed ID: 2958865
    [No Abstract] [Full Text] [Related]

  • 14. Anemia in patients on combined androgen block therapy for prostate cancer.
    Qian LX, Hua LX, Wu HF, Sui YG, Cheng SG, Zhang W, Li J, Wang XR.
    Asian J Androl; 2004 Dec 09; 6(4):383-4. PubMed ID: 15546035
    [Abstract] [Full Text] [Related]

  • 15. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H, Hara I, Eto H.
    BJU Int; 2005 Oct 09; 96(6):791-5. PubMed ID: 16153202
    [Abstract] [Full Text] [Related]

  • 16. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H, Kanetake H.
    Gan To Kagaku Ryoho; 2003 Jan 09; 30(1):43-9. PubMed ID: 12557704
    [Abstract] [Full Text] [Related]

  • 17. Combination therapy with castration and flutamide: today's treatment of choice for prostate cancer.
    Labrie F, Dupont A, Cusan L, Manhès G, Bergeron N, Lacourcière Y, Pineault S, Bélanger A, Monfette G, Emond J.
    J Steroid Biochem; 1989 Oct 09; 33(4B):817-21. PubMed ID: 2689788
    [Abstract] [Full Text] [Related]

  • 18. Combined treatment with flutamide and surgical or medical (LHRH agonist) castration in metastatic prostatic cancer.
    Lancet; 1986 Jan 04; 1(8471):48-9. PubMed ID: 2867292
    [No Abstract] [Full Text] [Related]

  • 19. Benefits of combination therapy with flutamide in patients relapsing after castration.
    Labrie F, Dupont A, Giguere M, Borsanyi JP, Lacourciere Y, Monfette G, Emond J, Bergeron N.
    Br J Urol; 1988 Apr 04; 61(4):341-6. PubMed ID: 3289676
    [Abstract] [Full Text] [Related]

  • 20. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
    Eastham JA, Sartor O.
    J Urol; 1998 Mar 04; 159(3):990. PubMed ID: 9474206
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.